Gastroenterology (journal)

June 17, 2025

Drug shows safety, efficacy for precancerous stomach lesions

The drug also showed promise that it could be the first therapeutic intervention against precancerous lesions in the stomach.

By Tom Wilemon
Eunyoung Choi, PhD
April 5, 2024

Eunyoung Choi’s gastric cancer research merits AACR-Debbie’s Dream funding

Ongoing research by Eunyoung Choi, PhD, into how cells transform into abnormal versions of themselves that are the precursors to stomach cancer has received support from the American Association for Cancer Research.

By Tom Wilemon
January 31, 2024

Fatty acids rewire energy supply chain in stomach cancer development

A study by Vanderbilt researchers has revealed how metabolic changes spurred by fatty acids contribute to the transformation of cells into abnormal versions of themselves that are the precursors to stomach cancer.

By Tom Wilemon
x-ray of stomach
October 5, 2023

Study validates pyrvinium as treatment to prevent stomach cancer

A Vanderbilt study found that a drug that has been used for decades for intestinal pinworms, can be repurposed as a preventative treatment for stomach cancer.

By Tom Wilemon
July 7, 2023

Study reveals new clue to gastric cancer

Researchers at Vanderbilt University Medical Center have uncovered evidence of fibroblast cells’ direct involvement in the development of gastric cancer.

By Bill Snyder
Anna Means, PhD, R. Daniel Beauchamp, MD, and colleagues are studying a group of proteins that are essential to the growth of colorectal cancer tumors.
July 21, 2022

Researchers find potential new target against colorectal cancer

By Bill Snyder
July 21, 2022

Difficulty swallowing linked to chronic opioid use: study

Vanderbilt researchers found that chronic use of opioid painkillers like hydrocodone and oxycodone significantly increases the risk of dysphagia, or difficulty swallowing.
By Bill Snyder
June 23, 2022

Study reveals how gastric cancer forms, suggests preventive treatment

Eunyoung Choi, PhD, assistant professor of Surgery, and colleagues identified for the first time that Trop2+/CD133+/CD166+ dysplastic stem cells are a key source of clonal evolution of dysplasia to multiple types of gastric cancer.
By Tom Wilemon
August 4, 2021

Study finds genetic factor undermines H. pylori treatment

Helicobacter pylori, a stomach-dwelling bacterium, is a strong risk factor for gastric cancer, peptic ulcers and other debilitating gastrointestinal disorders. Yet efforts to eradicate it using a combination of antibiotics and proton pump inhibitors (PPIs), which suppress gastric acid production, often fail.
By Bill Snyder
February 4, 2021

Potential biomarker for IBD severity, cancer risk identified

A selenium transport protein produced in the colon may be a novel biomarker for assessing disease severity and cancer risk in patients with inflammatory bowel disease.
By Leigh MacMillan
October 29, 2020

New markers of colorectal cancer risk

Vanderbilt epidemiologists identified new markers for colorectal cancer risk and characterized a previously unidentified tumor suppressor that regulates overall tumor volume in vivo.
By Sarah E. Glass
October 15, 2020

Possible COVID-19 “decoy”

It might be possible to use vesicles carrying the receptor for SARS-CoV-2, the virus that causes COVID-19, to bind the virus and prevent infection.
By Bill Snyder
October 15, 2020

Factor involved in stomach injury response identified

Researchers at Vanderbilt University Medical Center have identified a key factor that coordinates the body’s repair response to severe injury in the stomach caused, most commonly, by infection by the bacterium Helicobacter pylori.
By Bill Snyder